University of Pennsylvania at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Pennsylvania brings 4 presentations to ASH 2026 in New Orleans. Its program ranges across CAR T therapy, bleeding and clotting disorders and acute myeloid leukemia, including the long-term blood toxicity and second cancers that can follow CAR T. It also covers the design of factor VIII variants for gene therapy.
| Organization | ASH 2026 Attendance |
|---|---|
University of Pennsylvania Philadelphia, PA | |
Private research university in Philadelphia, home to the Perelman School of Medicine. | Symposium Fri Dec 11 7:00am–10:00am B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice Newer B-cell-targeting treatments for immune thrombocytopenia and how to fit them into care to achieve lasting platelet responses. Symposium Fri Dec 11 3:00pm–6:00pm Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum Getting relapsed lymphoma patients to CAR-T sooner, with earlier referral, bridging therapy, sequencing choices, and management of immune and nerve toxicities. Talk Rational Design of FVIII Variants for Gene Therapy: Linking Molecular Insight to Therapeutic Performance Engineering a better version of the clotting protein missing in hemophilia A for gene therapy, balancing stronger bleeding control against clot risk. Session JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy Every stage of the RNA life cycle, from splicing to chemical marks, shapes blood stem cells and blood cancers, pointing to new treatments. Talk Beyond Remission: Long-Term Hematopoietic Toxicity and Second Malignancies After CAR-T Cell Therapy Persistently low blood counts and second cancers after CAR-T therapy, including their frequency, causes, and how to monitor, prevent, and manage them. Talk Flt3 inhibitors in newly diagnosed and relapsed patients Evidence behind current Flt3 inhibitor use in newly diagnosed and relapsed acute myeloid leukemia, and where investigational approaches are heading. Talk Indications and Timing of Splenectomy in Hereditary Hemolytic Anemia When and how to remove the spleen in inherited red cell membrane and enzyme disorders, weighing benefit against lifelong infection and clotting risks. Session |
Instantly find 20 buyers from University of Pennsylvania
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction